Breast Cancer Therapeutics Market Size expected to witness growth to surpass USD 16 billion by 2023. (1)

1
Breast Cancer Therapeutics Market Size Expected
to Witness Growth to Surpass USD 16 billion by
2023.
2
Global Market Scenario Breast Cancer Therapeutics

• China breast cancer therapeutics market share
  accounted for over 15 of the Asia Pacific
  revenue.
• Australia accounted for over 10 and India
  contributed 3 to overall revenue generation,
  with the latter expected to grow at 9 CAGR over
  the forecast timeframe. 
• According to WHO statistics, it is the second
  most prevalent type of the disease globally, and
  the most widespread type in females.
• In women, it accounts for 20 of all invasive and
  13 of all female cancers, and is responsible for
  15 of all deaths caused by the disease globally,
  including both females and males.
• Every year, around 200,000 new cases in women and
  nearly 2,000 new cases in men are diagnosed.
• This disease occurs when cells in the breast show
  uncontrolled growth. Malignant tumors may
  metastatize or growing into the surrounding
  tissues.
• https//www.gminsights.com/industry-analysis/breas
  t-cancer-therapeutics-market

3
Continue.....

• It generally either begins in the lobules, which
  are the milk producing glands, or the inner
  lining of ducts, the passage that supply milk
  from lobules.
• Tumor occurring in the lobules is lobular
  carcinoma which represents 80 to 90 of all
  cases, while one which develops from the ducts is
  ductal carcinoma, representing 10 to 20 of all
  cases.
• In developed countries, the rates are much higher
  compared to their developing counterparts.
  However, in many developing nations, it is now
  rising abruptly due to changes in lifestyle,
  reproductive factors, and increased life
  expectancy.
• Mortality from breast cancer is a leading cause
  of death among women in developing countries, as
  well as in the developed world.
• Approximately 85 to 90 of all cases are caused
  by genetic abnormality, while the remaining are
  due to inherited abnormalities. 
• High degree of competition, potential side
  effects, growing number of medication options,
  and substitute branded drugs availability may
  adversely impact revenue in the coming years.
• Get more detail _at_ https//www.gminsights.com/indus
  try-analysis/breast-cancer-therapeutics-market

4
Continue.....

• On the basis of drug class, the industry is
  categorized into five major segments, namely,
  anti-metabolites, HER2 inhibitors, aromatase
  inhibitors, mitotic inhibitors, and hormone
  receptors.
• Based on the clinical study, the breast cancer
  therapeutics market can be segmented into Phase
  I, Phase II, and Phase III drugs. Of these, Phase
  III drugs are BKM120, Palbociclib (PD-0332991)
  Exemestane, Neratinib, DOXIL, ABP 980, NKTR-102,
  NK105, CT-P6, and Olaparib.
• Neratinib (developed by Puma Biotechnology), a
  clinical trial phase IIIdrug, will generate
  maximum revenue by 2023. It is highly powerful as
  an irreversible tyrosine kinase inhibitor (TKI).
• Available products comprise a wide range of
  treatment options, including hormonal,
  combination, targeted and chemotherapies.
  Chemotherapy remains the most important class of
  drugs for treatment however, the trend of using
  targeted drugs is on the rise.
• Treatment for the disease has been modernized in
  the past decades with increasing usage of
  targeted therapies. Perpendicular rise in the
  occurrence of disease makes it an industry where
  novel molecules and therapies are imperative.
• Get more detail _at_ https//www.gminsights.com/indus
  try-analysis/breast-cancer-therapeutics-market

5

Latest Research Report On Breast Cancer
Therapeutics Market _at_ https//www.gminsights.com/i
ndustry-analysis/breast-cancer-therapeutics-market
Download Latest Report Table of Contents _at_
https//www.gminsights.com/request-toc/upcoming/46
6
6
Stay In Touch You can visit us at
www.gminsights.com